The Surgical Infection Society (SIS) presents new evidence-based guidelines for the management of intra-abdominal infection (IAI) in the journal Surgical Infections. "These guidelines are critical in ...

Feb 7 (Reuters) - AbbVie (ABBV.N), opens new tab said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by ...

The FDA has approved aztreonam and avibactam (Emblaveo) in combination with metronidazole for adults who have limited or no alternative options for the treatment of complicated intra-abdominal ...

Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive ...

Feb. 6, 2003 — Ertapenem once daily was as efficacious and well tolerated for intra-abdominal infections as piperacillin/tazobactam four times daily, according to ...

EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by ...

Intra-abdominal infections encompass a spectrum from confined organ-based infections to diffuse peritonitis, frequently leading to sepsis and organ dysfunction. Effective management rests on three ...

Please provide your email address to receive an email when new articles are posted on . Advancements in imaging, risk stratification and antimicrobial stewardship are reflected in new guidelines for ...

Please provide your email address to receive an email when new articles are posted on . Emblaveo is the first monobactam/beta-lactamase inhibitor and antibiotic combination approved for this condition ...

The US Food and Drug Administration (FDA) has released a new draft guidance document pertaining to the development of new pharmaceutical therapies for the treatment of complicated intra-abdominal ...

The Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative options ...